Myriad Genetics (MYGN) 10-Q 6 Nov 19 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Sep. 30, 2019	Nov. 04, 2019
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Trading Symbol	MYGN
Entity Registrant Name	MYRIAD GENETICS INC
Entity Central Index Key	0000899923
Current Fiscal Year End Date	--06-30
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		74,389,024
Title of 12(b) Security	Public Common Stock, $0.01 par value
Security Exchange Name	NASDAQ
Entity File Number	0-26642
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-0494517
Entity Address, Address Line One	320 Wakara Way
Entity Address, City or Town	Salt Lake City
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84108
City Area Code	801
Local Phone Number	584-3600
Document Quarterly Report	true
Document Transition Report	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2019	Jun. 30, 2019
Current assets:
Cash and cash equivalents	$ 89.9	$ 93.2
Marketable investment securities	52.7	43.7
Prepaid expenses	14	16.6
Inventory	28.1	31.4
Trade accounts receivable	117	133.9
Prepaid taxes	23	25.1
Other receivables	4.8	4.7
Total current assets	329.5	348.6
Property, plant and equipment, net	55	57.3
Operating lease right-of-use assets	71.3
Long-term marketable investment securities	51.5	54.9
Intangibles, net	667.8	684.7
Goodwill	416.1	417.2
Total assets	1,591.2	1,562.7
Current liabilities:
Accounts payable	24	33.3
Accrued liabilities	73	78.9
Current maturities of operating lease liabilities	13
Short-term contingent consideration	3.3	3.4
Deferred revenue	2.1	2.2
Total current liabilities	115.4	117.8
Unrecognized tax benefits	22.1	21.7
Noncurrent operating lease liabilities	62.6
Other long-term liabilities	7.3	7.8
Contingent consideration	7.4	10.4
Long-term debt	225	233.5
Long-term deferred taxes	76.9	82.6
Total liabilities	516.7	473.8
Commitments and contingencies
Stockholders’ equity:
Common stock, 74.4 and 73.5 shares outstanding at September 30, 2019 and June 30, 2019 respectively	0.7	0.7
Additional paid-in capital	1,076.3	1,068
Accumulated other comprehensive loss	(7.5)	(5.4)
Retained earnings	5	25.6
Total Myriad Genetics, Inc. stockholders’ equity	1,074.5	1,088.9
Total stockholders' equity	1,074.5	1,088.9
Total liabilities and stockholders’ equity	$ 1,591.2	$ 1,562.7

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - shares shares in Millions	Sep. 30, 2019	Jun. 30, 2019	Jun. 30, 2018
Statement Of Financial Position [Abstract]
Common stock, shares outstanding	74.4	73.5	70.6

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Total revenue	$ 186.3	$ 202.3
Costs and expenses:
Research and development expense	21.3	21.1
Change in the fair value of contingent consideration	0.7	0.4
Selling, general, and administrative expense	135.5	129.9
Total costs and expenses	207.2	201.1
Operating income (loss)	(20.9)	1.2
Other income (expense):
Interest income	0.9	0.7
Interest expense	(2.9)	(2.2)
Other	0.6	1.1
Total other expense:	(1.4)	(0.4)
Income (loss) before income tax	(22.3)	0.8
Income tax provision (benefit)	(1.7)	1.6
Net income (loss)	(20.6)	(0.8)
Net loss attributable to non-controlling interest		(0.1)
Net income (loss) attributable to Myriad Genetics, Inc. stockholders	$ (20.6)	$ (0.7)
Earnings (loss) per share:
Basic	$ (0.28)	$ (0.01)
Diluted	$ (0.28)	$ (0.01)
Weighted average shares outstanding:
Basic	73.7	73
Diluted	73.7	73
Molecular Diagnostic Testing [Member]
Total revenue	$ 172	$ 189
Costs and expenses:
Total costs and expenses	41.2	42.3
Pharmaceutical and Clinical Services [Member]
Total revenue	14.3	13.3
Costs and expenses:
Total costs and expenses	$ 8.5	$ 7.4

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss) attributable to Myriad Genetics, Inc. stockholders	$ (20.6)	$ (0.7)
Unrealized gain (loss) on available-for-sale securities, net of tax	0	(0.2)
Change in foreign currency translation adjustment, net of tax	(2.2)	0.4
Comprehensive income (loss)	(22.8)	(0.5)
Comprehensive income attributable to non-controlling interest	0	0
Comprehensive income (loss) attributable to Myriad Genetics, Inc. shareholders	$ (22.8)	$ (0.5)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Millions	Total	Common Stock [Member]	Additional paid-in capital [Member]	Accumulated other comprehensive loss [Member]	Retained earnings (accumulated deficit) [Member]
Beginning Balance at Jun. 30, 2018	$ 966.1	$ 0.7	$ 915.4	$ (4.1)	$ 54.1
Issuance of common stock under share-based compensation plans	1.9		1.9
Share-based payment expense	127.4		127.4
Repurchase and retirement of common stock	7.7		7.7
Net income (loss)	(0.7)				(0.7)
Other comprehensive income, net of tax	(0.2)			(0.2)
Beginning Balance at Sep. 30, 2018	1,102.2	0.7	1,052.4	(4.3)	53.4
Beginning Balance at Jun. 30, 2019	1,088.9	0.7	1,068	(5.4)	25.6
Issuance of common stock under share-based compensation plans	(0.5)		(0.5)
Share-based payment expense	8.8		8.8
Net income (loss)	(20.6)				(20.6)
Other comprehensive income, net of tax	(2.1)			(2.1)
Beginning Balance at Sep. 30, 2019	$ 1,074.5	$ 0.7	$ 1,076.3	$ (7.5)	$ 5

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) attributable to Myriad Genetics, Inc. stockholders	$ (20.6)	$ (0.7)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	18.2	18.3
Non-cash interest expense	0.1	(1.3)
Loss (gain) on disposition of assets	(0.1)	(1)
Share-based compensation expense	8.8	7.7
Deferred income taxes	(5.1)	2.7
Unrecognized tax benefits	0.4	(2.6)
Change in fair value of contingent consideration	0.7	(0.4)
Changes in assets and liabilities:
Prepaid expenses	2.6	1.8
Trade accounts receivable	16.7	(3.3)
Other receivables	(0.1)	(0.3)
Inventory	3.1	3.5
Prepaid taxes	2.1	(3.6)
Accounts payable	(9.3)	(8.4)
Accrued liabilities	(1.7)	(4.4)
Deferred revenue		(0.2)
Net cash provided by operating activities	15.8	7.8
CASH FLOWS FROM INVESTING ACTIVITIES
Capital expenditures	(1.4)	(1.3)
Acquisitions, net of cash acquired		(279.6)
Purchases of marketable investment securities	(23.1)	(14.4)
Proceeds from maturities and sales of marketable investment securities	17.4	16.3
Net cash used in investing activities	(7.1)	(279)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from common stock issued under share-based compensation plans	(0.4)	2.1
Payment of contingent consideration recognized at acquisition	(3.3)
Net proceeds from revolving credit facility		290
Repayment of revolving credit facility	(8.6)	(40)
Net cash provided by (used in) financing activities	(12.3)	252.1
Effect of foreign exchange rates on cash and cash equivalents	0.3	1.5
Net decrease in cash and cash equivalents	(3.3)	(17.6)
Cash and cash equivalents at beginning of the period	93.2	110.9
Cash and cash equivalents at end of the period	$ 89.9	$ 93.3

Basis of Presentation

Basis of Presentation	3 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation	(1) BASIS OF PRESENTATION The accompanying condensed consolidated financial statements have been prepared by Myriad Genetics, Inc. (the “Company” or “Myriad”) in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The condensed consolidated financial statements herein should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2019, included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2019. Operating results for the three months ended September 30, 2019 may not necessarily be indicative of results to be expected for any other interim period or for the full year. The consolidated financial statements include the accounts of the Company’s majority-owned subsidiary, Assurex Canada, Ltd. which is 85% owned by Assurex Health, Inc. (“Assurex”), a wholly owned subsidiary of the Company, and 15% owned by the Centre for Addiction and Mental Health. Assurex Canada, Ltd. is a consolidated subsidiary of Assurex Health, Inc. The value of the non-controlling interest represents the portion of Assurex Canada, Ltd.’s profit or loss and net assets that is not held by Assurex Health, Inc. The Company attributes comprehensive income or loss of the subsidiary between the Company and the non-controlling interest based on the respective ownership interest. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Recent Accounting Pronouncements Recently Adopted Standards In February 2016, the FASB issued ASU 2016-02, Leases (“ASU 2016-02”). ASU 2016-02 amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and changing certain lessor accounting requirements. ASU 2016-02 also requires entities to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. On July 1, 2019, the Company adopted ASU 2016-02 under the modified retrospective approach by initially applying ASU 2016-02 at the adoption date, rather than at the beginning of the earliest comparative period presented. Results for the three months ended September 30, 2019 are presented under ASU 2016-02. Prior period amounts were not adjusted and continue to be reported under previous lease accounting guidance. Under ASU 2016-02, the Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (“ROU”) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable. As the implicit rate in the Company's leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating the Company’s incremental borrowing rates, the Company gives consideration to its credit risk, term of the lease, total lease payments and adjust for the impacts of collateral, as necessary. The lease term used may reflect any option to extend or terminate the lease when it is reasonably certain the Company will exercise such options. Lease expenses for the Company's operating leases are recognized on a straight-line basis over the lease term. ASU 2016-02 provides a number of optional practical expedients in transitioning to ASU 2016-02. The Company has elected the package of practical expedients to avoid reassessing under ASU 2016-02 prior conclusions about lease identification, lease classification and initial direct costs. The Company has also elected the practical expedient allowing the use of hindsight in determining the lease term and assessing impairment of right-of-use ROU assets based on all facts and circumstances through the effective date of the new standard. ASU 2016-02 also provides practical expedients for ongoing lease accounting. The Company has elected the recognition exemption for short-term leases for all leases that qualify. Under this exemption, the Company will not recognize ROU assets or lease liabilities for those leases that qualify as a short-term lease (leases with lease terms of 12 months or less), which includes not recognizing ROU assets or lease liabilities for existing short-term leases in transition. The Company also has elected the practical expedient avoid separating lease and non-lease components for any of its leases within its existing classes of assets. The Company recognized operating lease liabilities of $78.8 and right-of-use assets related to operating leases totaling $74.5 as of the adoption date. These are presented as “Current maturities of operating lease liabilities” for a total of $13.1, “Noncurrent operating lease liabilities” for a total of $65.7, and “Operating lease right-of-use assets” for a total of $74.5 on the Company’s consolidated balance sheet. No adjustments to the beginning retained earnings balance were required. Standards Effective in Future Years and Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326) (“ASU 2016-13”) which introduces new guidance for the accounting for credit losses on certain instruments within its scope. ASU 2016-13 introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. For trade receivables, the Company will be required to use a forward-looking expected loss model rather than the incurred loss model for recognizing credit losses, which reflects losses that are probable. Credit losses relating to available-for-sale debt securities will also be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. ASU 2016-13 is effective for fiscal years beginning after December 31, 2019, including interim periods within those years. Early application of the guidance is permitted for all entities for fiscal years beginning after December 15, 2018, including the interim periods within those fiscal years. Application of the amendments is through a cumulative-effect adjustment to retained earnings as of the effective date. The Company is currently evaluating the impact of ASU 2016-13 on its consolidated financial statements .

Revenue

Revenue	3 Months Ended
	Sep. 30, 2019
Revenue From Contract With Customer [Abstract]
Revenue	(2) REVENUE The following table presents detail regarding the composition of our total revenue by product and U.S versus rest of world, “RoW”: Three months ended September 30, 2019 2018 (In millions) U.S. RoW Total U.S. RoW Total Molecular diagnostic revenues: Hereditary Cancer Testing $ 100.6 $ 3.9 $ 104.5 $ 113.5 $ 2.8 $ 116.3 GeneSight 22.7 — 22.7 29.3 — 29.3 Prenatal 23.5 — 23.5 18.1 — 18.1 VectraDA 11.0 — 11.0 13.0 — 13.0 Prolaris 6.5 — 6.5 6.2 — 6.2 EndoPredict 0.5 1.8 2.3 0.3 2.1 2.4 Other 1.4 0.1 1.5 3.6 0.1 3.7 Total molecular diagnostic revenue 166.2 5.8 172.0 184.0 5.0 189.0 Pharmaceutical and clinical service revenue 8.5 5.9 14.3 7.6 5.7 13.3 Total revenue $ 174.7 $ 11.7 $ 186.3 $ 191.6 $ 10.7 $ 202.3 The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets. Occasionally customers make payments prior to the Company's performance of its contractual obligations. When this occurs the Company records a contract liability as deferred revenue. A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below: Three months ended September 30, 2019 2018 Deferred revenue - beginning balance $ 2.2 $ 2.6 Revenue recognized (0.4 ) (1.7 ) Prepayments 0.3 1.6 Deferred revenue - Ending Balance $ 2.1 $ 2.5 Myriad Companies generate revenue by performing molecular diagnostic testing and pharmaceutical & clinical services. Revenue from the sale of molecular diagnostic tests and pharmaceutical and clinical services is recorded at the invoiced amount net of any discounts or contractual allowances. The Company has determined that the communication of test re sults or the completion of clinical and pharmaceutical services indicates transfer of control for revenue recognition purposes. In accordance with ASU 2014-09, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company’s right to payment is in an amount that directly corresponds with the value of Company’s performance to date. However, periodically the Company enters into arrangements with customers to provide diagnostic testing and/or pharmaceutical and clinical services that may have terms longer than one year and include multiple performance obligations. As of September 30, 2019, the aggregate amount of the transaction price of such contracts that is allocated to the remaining performance obligations is $1.8. The Company provides discounts such as early payment, self-pay and volume discounts to its customers. In determining the transaction price, Myriad includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. The Company applies the expected value method for sales where the Company has a large number of contracts with similar characteristics. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. The Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. The Company excludes from the measurement of transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from a customer for e.g. sales tax, value added tax etc. The Company applies the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly no costs incurred to obtain or fulfill a contract have been capitalized. The Company also applies the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and vast majority of payments terms have a payback period of less than one year. During the three months ended September 30, 2019, the Company recognized a $10.9 decrease in revenue, which resulted in an ($0.11) impact to EPS, for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third party payors.

Acquisitions

Acquisitions	3 Months Ended
	Sep. 30, 2019
Business Combinations [Abstract]
Acquisitions	(3) ACQUISITIONS Acquisition of Counsyl, Inc. On July 31, 2018, the Company completed the acquisition of Counsyl, Inc. (“Counsyl”), a leading provider of genetic testing and DNA analysis services, pursuant to the Agreement and Plan of Merger (the “Merger Agreement”), dated May 25, 2018. Pursuant to the terms of the Merger Agreement, Myriad Merger Sub, Inc., a newly-created wholly-owned subsidiary of the Company, was merged with and into Counsyl, with Counsyl continuing as the surviving corporation and a wholly-owned subsidiary of Myriad. The Company believes the acquisition allows for greater entry into the high-growth reproductive testing market, with the ability to become a leader in women’s health genetic testing. The Company acquired Counsyl for total consideration of $405.9, consisting of $278.5 in cash, financed in part by the Amendment to the Facility (see Note 8) and 2,994,251 shares of common stock issued, valued at $127.4. The shares were issued and valued as of July 31, 2018 at a per share market closing price of $42.53. To complete the purchase transaction, the Company incurred approximately $6.8 of acquisition costs, which were recorded as selling, general and administrative expenses in the period incurred. Of the cash consideration, $5.0 was deposited into an escrow account to fund any post-closing adjustments payable to Myriad based upon differences between the estimated working capital and the actual working capital of Counsyl at closing. Consideration transferred was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values as of the acquisition date. Management estimated the fair value of tangible and intangibl e assets and liabilities in accordance with the applicable accounting guidance for business combinations and utilized the services of third-party valuation consultants. The allocation of the consideration transferred was finalized within the measurement pe riod (which was up to one year from the acquisition date) . Estimated Fair Value Current assets $ 42.5 Intangible assets 290.0 Equipment 18.2 Other assets 0.1 Goodwill 99.3 Current liabilities (19.6 ) Long term liabilities (0.1 ) Deferred tax liability (9.2 ) Total fair value purchase price $ 421.2 Less: Cash acquired (15.3 ) Total consideration transferred $ 405.9 Identifiable Intangible Assets Through its acquisition of Counsyl, the Company acquired intangible assets that consisted of developed screening processes with an estimated fair value of $290.0. The fair values of these developed screening processes were estimated using a probability-weighted income approach that discounts expected future cash flows to present value. Under the probability-weighted income approach, the estimated net cash flows from these developed screening processes were discounted using a discount rate of 12.5%, which is based on the estimated internal rate of return for the acquired developed screening processes and represents the rate that market participants may use to value these intangible assets. The Company will amortize these intangible assets on a straight-line basis over their estimated useful lives of 12 years. Goodwill The goodwill represents the excess of consideration transferred over the fair value of assets acquired and liabilities assumed from Counsyl and is attributable to the benefits expected from combining the Company’s expertise with Counsyl’s technology and customer insights and the opportunity to integrate genetic screening into clinical practice with OBGYNs. Changes in goodwill since the Counsyl acquisition as of September 30, 2019 are shown below: Carrying amount Balance September 30, 2018 $ 94.9 Fair value adjustment to equipment 0.7 Intangible adjustment 2.9 Working capital adjustment (1.1 ) Change in deferred tax liability 1.9 Balance September 30, 2019 $ 99.3 This goodwill is not deductible for income tax purposes. Pro Forma Information (Unaudited) The unaudited pro-forma results presented below include the effects of the Counsyl acquisition as if it had been consummated as of July 1, 2017, with adjustments to give effect to pro forma events that are directly attributable to the acquisition, which includes adjustments related to the amortization of acquired intangible assets, interest income and expense, and depreciation. The unaudited pro forma results do not reflect any operating efficiency or potential cost savings that may result from the consol idation of Counsyl. Accordingly, these unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operation of the combined company would have been if the acquisition had occur red at the beginning of the period presented, nor are they indicative of future results of operations and are not necessarily indicative of results that might have been achieved had the acquisition been consummated as of July 1, 2017. Three months ended September 30, 2019 2018 Revenue $ 186.3 $ 212.5 Income (loss) from operations (20.9 ) 11.5 Net income (loss) (20.6 ) 8.6 Earnings (loss) per share, basic $ (0.28 ) $ 0.11 Earnings (loss) per share, diluted $ (0.28 ) $ 0.11

Marketable Investment Securitie

Marketable Investment Securities	3 Months Ended
	Sep. 30, 2019
Investments Debt And Equity Securities [Abstract]
Marketable Investment Securities	(4) MARKETABLE INVESTMENT SECURITIES The Company has classified its marketable investment securities as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated other comprehensive loss in stockholders’ equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. The Company’s cash equivalents consist of short-term, highly liquid investments that are readily convertible to known amounts of cash. The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at September 30, 2019 and June 30, 2019 were as follows: Gross Gross unrealized unrealized Amortized holding holding Estimated cost gains losses fair value At September 30, 2019: Cash and cash equivalents: Cash $ 67.2 $ — $ — $ 67.2 Cash equivalents 22.7 — — $ 22.7 Total cash and cash equivalents 89.9 — — 89.9 Available-for-sale: Corporate bonds and notes 68.7 0.4 69.1 Municipal bonds 15.0 0.1 15.1 Federal agency issues 7.0 — — 7.0 US government securities 12.9 0.1 — 13.0 Total $ 193.5 $ 0.6 $ — $ 194.1 Gross Gross unrealized unrealized Amortized holding holding Estimated cost gains losses fair value At June 30, 2019: Cash and cash equivalents: Cash $ 68.7 $ — $ — $ 68.7 Cash equivalents 24.5 — — 24.5 Total cash and cash equivalents 93.2 — — 93.2 Available-for-sale: Corporate bonds and notes 64.0 0.6 — 64.6 Municipal bonds 15.3 — — 15.3 Federal agency issues 9.0 — — 9.0 US government securities 9.7 — — 9.7 Total $ 191.2 $ 0.6 $ — $ 191.8 Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities are as follows at September 30, 2019: Amortized Estimated cost fair value Cash $ 67.2 $ 67.2 Cash equivalents 22.7 22.7 Available-for-sale: Due within one year 54.9 55.0 Due after one year through five years 48.7 49.2 Due after five years — — Total $ 193.5 $ 194.1

Property, Plant and Equipment,

Property, Plant and Equipment, Net	3 Months Ended
	Sep. 30, 2019
Property Plant And Equipment [Abstract]
Property, Plant and Equipment, Net	(5) PROPERTY, PLANT AND EQUIPMENT, NET September 30, June 30, 2019 2019 Land $ 2.2 $ 2.3 Buildings and improvements 18.2 18.8 Leasehold improvements 31.1 31.0 Equipment 115.5 117.1 167.0 169.2 Less accumulated depreciation (112.0 ) (111.9 ) Property, plant and equipment, net $ 55.0 $ 57.3 Three months ended September 30, 2019 2018 Depreciation expense $ 2.9 $ 4.9

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Sep. 30, 2019
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	(6) GOODWILL AND INTANGIBLE ASSETS Goodwill The Company has recorded goodwill of $416.1 from the acquisitions of Counsyl that was completed on July 31, 2018, Assurex that was completed on August 31, 2016, Sividon Diagnostics GmbH (“Sividon”) that was completed on May 31, 2016, Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG (the “Clinic”) that was completed on February 27, 2015, Crescendo Bioscience, Inc. that was completed on February 28, 2014 and Rules-Based Medicine, Inc. that was completed on May 31, 2011. Of this goodwill, $350.8 relates to the Company’s diagnostic segment and $65.3 relates to the other segment. The following summarizes changes to the goodwill balance for the three months ended September 30, 2019: Carrying amount Ending balance June 30 2019 $ 417.2 Acquisitions — Translation adjustments (1.1 ) Ending balance September 30, 2019 $ 416.1 Intangible Assets Intangible assets primarily consist of amortizable assets of purchased licenses and technologies, customer relationships, and trade names as well as non-amortizable intangible assets of in-process technologies and research and development. The following summarizes the amounts reported as intangible assets: Gross Carrying Accumulated Amount Amortization Net At September 30, 2019: Purchased licenses and technologies $ 814.5 $ (171.5 ) $ 643.0 Customer relationships 4.7 (3.9 ) 0.8 Trademarks 3.0 (1.3 ) 1.7 Total amortized intangible assets 822.2 (176.7 ) 645.5 In-process research and development 22.3 — 22.3 Total unamortized intangible assets 22.3 — 22.3 Total intangible assets $ 844.5 $ (176.7 ) $ 667.8 Gross Carrying Accumulated Amount Amortization Net At June 30, 2019: Purchased licenses and technologies $ 815.7 $ (156.6 ) $ 659.1 Customer relationships 4.6 (3.8 ) 0.8 Trademarks 3.0 (1.2 ) 1.8 Total amortized intangible assets 823.3 (161.6 ) 661.7 In-process research and development 23.0 — 23.0 Total unamortized intangible assets 23.0 — 23.0 Total intangible assets $ 846.3 $ (161.6 ) $ 684.7 The Company recorded amortization expense during the respective periods for these intangible assets as follows: Three months ended September 30, 2019 2018 Amortization of intangible assets $ 15.3 $ 13.4

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Sep. 30, 2019
Payables And Accruals [Abstract]
Accrued Liabilities	(7) ACCRUED LIABILITIES September 30, June 30, 2019 2019 Employee compensation and benefits $ 45.2 $ 48.8 Accrued taxes payable 7.2 3.0 Qui tam settlement 9.1 9.1 Other 11.5 18.0 Total accrued liabilities $ 73.0 $ 78.9

Long-Term Debt

Long-Term Debt	3 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Long-Term Debt	(8) LONG-TERM DEBT On December 23, 2016, the Company entered into a senior secured revolving credit facility (the “Facility”) by and among Myriad, as borrower, with the lenders from time to time party thereto. On July 31, 2018, the Company entered into Amendment No. 1 (the “Amended Facility”) which effects an “amend and extend” transaction with respect to the Facility by which the maturity date thereof was extended to July 31, 2023 and the maximum aggregate principal commitment was increased from $300.0 to $350.0. This was accounted for as a modification pursuant to guidance in ASC 470-50. Pursuant to the Amended Facility, Myriad borrowed revolving loans in an aggregate principal amount of $300.0 with $1.8 in upfront fees and $0.3 debt issuance costs recorded as a debt discount to be amortized over the term of the Amended Facility. The current balance of the net long-term debt is $225.0. There are no scheduled principal payments of the Amended Facility prior to its maturity date. The proceeds of the Amende d Facility were used to: (i) refinance in full the obligations under the Facility, (ii) finance the acquisition of Counsyl (See Note 3), (iii) pay fees, commissions, transactions costs and expenses incurred in connection with the foregoing, and (iv) for wo rking capital and other general corporate purposes. The Amended Facility contains customary loan terms, interest rates, representations and warranties, affirmative and negative covenants, in each case, subject to customary limitations, exceptions and exclusions. The Amended Facility also contains certain customary events of default. Covenants in the Amended Facility impose operating and financial restrictions on the Company. These restrictions may prohibit or place limitations on, among other things, the Company’s ability to incur additional indebtedness, create certain types of liens, complete mergers or consolidations, and/or change in control transactions. The Amended Facility may also prohibit or place limitations on the Company’s ability to sell assets, pay dividends or provide other distributions to shareholders. The Company must maintain specified leverage and interest ratios measured as of the end of each quarter as a financial covenant in the Amended Facility. We were in compliance with all financial covenants at September 30, 2019. During the quarter ended September 30, 2019, the Company made $8.6 in principal repayments. The Amended Facility is secured by a first-lien security interest in substantially all of the assets of Myriad and certain of its domestic subsidiaries and each such domestic subsidiary of Myriad has guaranteed the repayment of the Amended Facility. Amounts outstanding under the Amended Facility and Facility were as follows: September 30, June 30, 2019 2019 Long-term debt $ 226.6 $ 235.0 Long-term debt discount (1.6 ) (1.5 ) Net long-term debt $ 225.0 $ 233.5

Other Long Term Liabilities

Other Long Term Liabilities	3 Months Ended
	Sep. 30, 2019
Other Liabilities Disclosure [Abstract]
Other Long Term Liabilities	(9) OTHER LONG TERM LIABILITIES September 30, June 30, 2019 2019 Pension obligation 6.8 6.8 Other 0.5 1.0 Total other long term liabilities $ 7.3 $ 7.8 The Company has two non-contributory defined benefit pension plans for certain Clinic employees. Participation in the plans excludes those employees hired after 2002. As of September 30, 2019 the fair value of the plan assets were approximately $0.1 resulting in a net pension liability of $6.8.

Preferred and Common Stockholde

Preferred and Common Stockholder's Equity	3 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Preferred and Common Stockholder's Equity	(10) PREFERRED AND COMMON STOCKHOLDER’S EQUITY The Company is authorized to issue up to 5.0 shares of preferred stock, par value $0.01 per share. There were no preferred shares outstanding at September 30, 2019. The Company is authorized to issue up to 150.0 shares of common stock, par value $0.01 per share. There were 74.4 shares issued and outstanding at September 30, 2019. Common shares issued and outstanding Three months ended Year ended September 30, June 30, 2019 2019 Beginning common stock issued and outstanding 73.5 70.6 Common stock issued upon exercise of options and employee stock plans 0.9 4.5 Repurchase and retirement of common stock — (1.6 ) Common stock issued and outstanding at end of period 74.4 73.5 Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding. In periods when the Company has a net loss, stock awards are excluded from the calculation of diluted net loss per share as their inclusion would have an antidilutive effect. The following is a reconciliation of the denominators of the basic and diluted earnings per share (“EPS”) computations: Three months ended September 30, 2019 2018 Denominator: Weighted-average shares outstanding used to compute basic EPS 73.7 73.0 Effect of dilutive shares — — Weighted-average shares outstanding and dilutive securities used to compute diluted EPS 73.7 73.0 Certain outstanding options and restricted stock units (“RSUs”) were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows: Three months ended September 30, 2019 2018 Anti-dilutive options and RSU's excluded from EPS computation 1.7 4.1 Stock Repurchase Program In June 2016, the Company’s Board of Directors authorized an eighth share repurchase program of $200.0 of the Company’s outstanding common stock. The Company plans to repurchase its common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by the Company’s management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors. As of September 30, 2019, the Company has $110.7 remaining on its current share repurchase authorization. The Company uses the par value method of accounting for its stock repurchases. As a result of the stock repurchases, the Company reduced common stock and additional paid-in capital and recorded charges to accumulated deficit. The shares retired, aggregate common stock and additional paid-in capital reductions, and related charges to accumulated deficit for the repurchases for three months ended September 30, 2019 and 2018 were as follows: Three months ended September 30, 2019 2018 Shares purchased and retired — — Common stock and additional paid-in-capital reductions $ — $ — Charges to retained earnings $ — $ —

Income Taxes

Income Taxes	3 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	(11) INCOME TAXES In order to determine the Company’s quarterly provision for income taxes, the Company used an estimated annual effective tax rate that is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates. The Tax Act Cuts and Jobs Act reduces the federal corporate tax rate to 21% for the fiscal year ending June 30, 2020. Certain significant or unusual items are separately recognized in the quarter during which they occur and can be a source of variability in the effective tax rate from quarter to quarter. Certain significant or unusual items are separately recognized in the quarter during which they occur and can be a source of variability in the effective tax rate from quarter to quarter. Income tax benefit for the three months ended September 30, 2019 was $(1.7), or approximately 7.6% of pre-tax income compared to income tax expense of $1.6, or approximately 200.0% of pre-tax income, for the three months ended September 30, 2018 . Income tax expense for the three months ended September 30, 2019 is based on the Company’s estimated annual effective tax rate for the full fiscal year ending June 30, 2020, adjusted by discrete items recognized during the period. For the three months ended Sept ember 30, 2019, the Company’s recognized effective tax rate differs from the U.S. federal statutory rate primarily due to the effect of the release of uncertain tax liabilities, state income taxes, acquisition transaction costs, and differences related to the tax effect of equity compensation expense and the deduction realized when exercised, released or sold. The Company files U.S., foreign and state income tax returns in jurisdictions with various statutes of limitations. The Company is currently under audit by the state of New Jersey for the fiscal years June 30, 2013 through 2017; the state of New York and Massachusetts for the fiscal years June 30, 2014 through 2016; Germany for the fiscal years June 30, 2013 through 2015; and Switzerland for the fiscal years June 30, 2015 through 2016. Annual and interim tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued.

Share-Based Compensation

Share-Based Compensation	3 Months Ended
	Sep. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Compensation	(12) SHARE-BASED COMPENSATION On November 30, 2017, the Company’s shareholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (the “2017 Plan”). The 2017 Plan allows the Company, under the direction of the Compensation Committee of the Board of Directors, to make grants of restricted and unrestricted stock awards to employees, consultants and directors. As of September 30, 2019, the Company may grant additional shares of common stock under the 2017 Plan with respect to the 0.4 options outstanding under our 2003 Plan and 5.3 options and restricted stock units outstanding under our 2010 Plan, that expire or are cancelled without delivery of shares of common stock. If an RSU awarded under the 2017 Plan is cancelled or forfeited without the issuance of shares of common stock, the unissued or reacquired shares, which were subject to the RSU, shall again be available for issuance pursuant to the 2017 Plan. The number of shares, terms, and vesting periods are determined by the Company’s Board of Directors or a committee thereof on an option-by-option basis. Options generally vest ratably over service periods of four years. Options granted after December 5, 2012 expire eight years from the date of grant, and options granted prior to that date generally expire ten years from the date of grant. In September 2014, the Company began issuing restricted stock units (“RSUs”) in lieu of stock options. RSUs granted to employees generally vest ratably over four years on the anniversary date of the designated day of the last week of the month in which the RSUs are granted. The number of RSUs awarded to certain executive officers may be reduced if certain additional performance metrics are not met. Options and RSUs granted to our non-employee directors vest in full upon completion of one year of service on the Board following the date of the grant. Stock Options A summary of the stock option activity under the Company’s plans for the three months ended September 30, 2019 is as follows: Number of shares Weighted average exercise price Options outstanding at June 30, 2019 5.5 $ 24.45 Options granted — $ — Less: Options exercised (0.4 ) $ 22.87 Options canceled or expired (0.1 ) $ 30.00 Options outstanding at September 30, 2019 5.0 $ 24.39 Options exercisable at September 30, 2019 5.0 $ 24.39 As of September 30, 2019, there was no unrecognized share-based compensation expense related to stock options. Restricted Stock Units A summary of the RSU activity under the Company’s plans for the three months ended September 30, 2019 is as follows: Number of shares Weighted average grant date fair value RSUs outstanding at June 30, 2019 2.4 $ 37.70 RSUs granted 1.2 $ 29.89 Less: RSUs vested (0.8 ) $ 36.00 RSUs canceled (0.1 ) $ 46.00 RSUs outstanding at September 30, 2019 2.7 $ 34.71 As of September 30, 2019, there was $39.2 of total unrecognized share-based compensation expense related to RSUs that will be recognized over a weighted-average period of 2.7 years. This unrecognized compensation expense is equal to the fair value of RSUs expected to vest. Employee Stock Purchase Plan The Company also has an Employee Stock Purchase Plan that was approved by shareholders in 2012 (the “2012 Purchase Plan”), under which 2.0 shares of common stock have been authorized. Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period. As of September 30, 2019, approximately 0.6 shares of common stock are available for issuance under the 2012 Purchase Plan. Share-Based Compensation Expense Share-based compensation expense recognized and included in the condensed consolidated statements of income and comprehensive income was allocated as follows: Three months ended September 30, 2019 2018 Cost of molecular diagnostic testing $ 0.2 $ 0.2 Cost of pharmaceutical and clinical services 0.1 0.1 Research and development expense 1.5 1.2 Selling, general, and administrative expense 7.0 6.2 Total share-based compensation expense $ 8.8 $ 7.7

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	(13) FAIR VALUE MEASUREMENTS The fair value of the Company’s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value of contingent consideration related to the Sividon and Assurex acquisitions as well as the long-term debt were categorized as a level 3 liability, as the measurement amount is based primarily on significant inputs not observable in the market. The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels: Level 1—quoted prices in active markets for identical assets and liabilities. Level 2—observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Some of the Company’s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities. Level 3—unobservable inputs. All of the Company’s financial instru ments are valued using quoted prices in active markets or based on other observable inputs. For Level 2 securities, the Company uses a third party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. For Level 3 contingent consideration, the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected earn out liability. This fair value measurement is considered a Level 3 measurement because the Company es timates projections during the earn out period utilizing various potential pay-out scenarios. Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as we ll as a specific risk premium associated with the riskiness of the earn-out itself, the related projections, and the overall business. The contingent earn-out liabilities are classified as a component of long-term and short-term contingent consideration i n the Company’s consolidated balance sheets. Changes to the earn-out liabilities are reflected in change in the fair value of contingent consideration in our consolidated statements of operations. Changes to the unobservable inputs could have a material i mpact on the Company’s financial statements. The fair value of our long-term debt, which we consider a Level 3 measurement, is estimated using discounted cash flow analyses, based on the Company’s current estimated incremental borrowing rates for similar borrowing arrangements. The fair value of long-term debt is estimated to be $224.7 at September 30, 2019. The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis: Level 1 Level 2 Level 3 Total September 30, 2019 Money market funds (a) $ 13.3 $ — $ — $ 13.3 Corporate bonds and notes 1.5 69.1 — 70.6 Municipal bonds — 15.1 — 15.1 Federal agency issues — 7.0 — 7.0 US government securities — 13.0 — 13.0 Contingent consideration — — (10.7 ) (10.7 ) Total $ 14.8 $ 104.2 $ (10.7 ) $ 108.3 (a) Money market funds are primarily comprised of exchange traded funds and accrued interest. Level 1 Level 2 Level 3 Total June 30, 2019 Money market funds (a) $ 17.2 $ — $ — $ 17.2 Corporate bonds and notes 2.5 64.4 — 66.9 Municipal bonds — 15.4 — 15.4 Federal agency issues — 9.0 — 9.0 US government securities — 9.8 — 9.8 Contingent consideration — — (13.8 ) (13.8 ) Total $ 19.7 $ 98.6 $ (13.8 ) $ 104.5 (a) Money market funds are primarily comprised of exchange traded funds and accrued interest. The following table reconciles the change in the fair value of the contingent consideration during the periods presented: Carrying amount Balance June 30, 2019 $ 13.8 Payment of contingent consideration (3.3 ) Change in fair value recognized in the income statement (0.7 ) Translation adjustments recognized in other comprehensive income 0.9 Ending balance September 30, 2019 $ 10.7

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Sep. 30, 2019
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	(14) COMMITMENTS AND CONTINGENCIES In July 2019, the Company resolved the complaint filed by a qui tam relator in October 2017 in the United States District Court for the District of South Carolina. The complaint was the basis of the Office of Inspector General (OIG) subpoena dated February 2018 regarding Medicare billing practices relating to the Company’s hereditary cancer testing from 2014 to 2018. After a 17-month investigation, the Department of Justice declined to intervene in the case. The Company believes this demonstrated that the key allegations made in the complaint were false. In order to avoid a lengthy and distracting litigation with the qui tam relator, the Company entered into a settlement agreement on July 18, 2019 under which the Company would pay $9.1 to the qui tam relator in order to settle the matter. The Company paid the settlement amount of $9.1 in October 2019. The Company denies any wrongdoing and does not anticipate any material change in its billing practices. In addition, the Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. As of September 30, 2019, the management of the Company believes any reasonably possible liability that may result from the resolution of these matters will not have a material adverse effect on the Company’s consolidated financial position, operating results, or cash flows. The Company leases certain office spaces and research and development laboratory facilities, vehicles, and office equipment with remaining lease terms ranging from one to six years. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options which allows the Company to, at its election, renew or extend the lease for a fixed or indefinite period of time. These optional periods have not been considered in the determination of the right-of-use-assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. For the three months ended September 30, 2019, the Company incurred $4.6 in lease costs which are included in operating expenses in the consolidated statement of operations in relation to these operating leases. Of such lease costs, $0.6 was variable lease expense and $0.1 was short-term lease expense, and neither of them were included in the measurement of the Company's operating ROU assets and lease liabilities. The variable rent expense is comprised primarily of the Company's proportionate share of operating expenses, property taxes, and insurance and is classified as lease expense due to the Company's election to not separate lease and non-lease components. As of September 30, 2019, the maturities of the Company’s operating lease liabilities were as follows: Fiscal year ending: 2020 $ 11.9 2021 14.9 2022 13.7 2023 12.6 2024 12.3 Thereafter 19.3 Total lease payments $ 84.7 As of September 30, 2019, the weighted average remaining lease term is 6.0 years and the weighted average discount rate used to determine the operating lease liability was 3.87%. Disclosures related to periods prior to the adoption of ASU 2016-02 The following table summarizes the future minimum lease payments as of June 30, 2019: Fiscal year ending: 2020 $ 15.1 2021 14.1 2022 13.1 2023 12.2 2024 11.9 Thereafter 19.1 Total lease payments $ 85.5

Employee Deferred Savings Plan

Employee Deferred Savings Plan	3 Months Ended
	Sep. 30, 2019
Postemployment Benefits [Abstract]
Employee Deferred Savings Plan	(15) EMPLOYEE DEFERRED SAVINGS PLAN The Company has a deferred savings plan which qualifies under Section 401(k) of the Internal Revenue Code. Substantially all of the Company’s U.S. employees are covered by the plan. The Company makes matching contributions of 50% of each employee’s contribution with the employer’s contribution not to exceed 4% of the employee’s compensation. The Company recorded contributions to the plan as follows: Three months ended September 30, 2019 2018 Deferred savings plan contributions $ 2.5 $ 2.0

Segment and Related Information

Segment and Related Information	3 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Segment and Related Information	(16) SEGMENT AND RELATED INFORMATION The Company’s business is aligned with how the Chief Operating Decision Maker reviews performance and makes decisions in managing the Company. The business units have been aggregated into two reportable segments: (i) diagnostics and (ii) other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology. Segment revenue and operating income (loss) were as follows during the periods presented: Diagnostics Other Total Three months ended September 30, 2019 Revenues $ 170.4 $ 15.9 $ 186.3 Depreciation and amortization 16.9 1.3 18.2 Segment operating income (loss) 17.3 (38.2 ) (20.9 ) Three months ended September 30, 2018 Revenues $ 189.0 $ 13.3 $ 202.3 Depreciation and amortization 17.0 1.3 18.3 Segment operating income 27.6 (26.4 ) 1.2 Three months ended September 30, 2019 2018 Total operating income for reportable segments $ (20.9 ) $ 1.2 Unallocated amounts: Interest income 0.9 0.7 Interest expense (2.9 ) (2.2 ) Other 0.6 1.1 Income (loss) from operations before income taxes (22.3 ) 0.8 Income tax provision (1.7 ) 1.6 Net income (loss) (20.6 ) (0.8 ) Net loss attributable to non-controlling interest — (0.1 ) Net income (loss) attributable to Myriad Genetics, Inc. stockholders $ (20.6 ) $ (0.7 )

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	3 Months Ended
	Sep. 30, 2019
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	(17) SUPPLEMENTAL CASH FLOW INFORMATION Three months ended September 30, 2019 2018 Cash paid during the period for income taxes $ 0.2 $ 4.9 Cash paid for interest 2.8 0.9 Establishment of operating lease right-of-use assets and lease liabilities Operating lease right-of-use assets $ 74.5 $ — Operating lease liabilities (78.8 ) — Accrued liabilities and other long-term liabilities 4.3 —

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation	The accompanying condensed consolidated financial statements have been prepared by Myriad Genetics, Inc. (the “Company” or “Myriad”) in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The condensed consolidated financial statements herein should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2019, included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2019. Operating results for the three months ended September 30, 2019 may not necessarily be indicative of results to be expected for any other interim period or for the full year. The consolidated financial statements include the accounts of the Company’s majority-owned subsidiary, Assurex Canada, Ltd. which is 85% owned by Assurex Health, Inc. (“Assurex”), a wholly owned subsidiary of the Company, and 15% owned by the Centre for Addiction and Mental Health. Assurex Canada, Ltd. is a consolidated subsidiary of Assurex Health, Inc. The value of the non-controlling interest represents the portion of Assurex Canada, Ltd.’s profit or loss and net assets that is not held by Assurex Health, Inc. The Company attributes comprehensive income or loss of the subsidiary between the Company and the non-controlling interest based on the respective ownership interest. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recently Adopted Standards In February 2016, the FASB issued ASU 2016-02, Leases (“ASU 2016-02”). ASU 2016-02 amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and changing certain lessor accounting requirements. ASU 2016-02 also requires entities to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. On July 1, 2019, the Company adopted ASU 2016-02 under the modified retrospective approach by initially applying ASU 2016-02 at the adoption date, rather than at the beginning of the earliest comparative period presented. Results for the three months ended September 30, 2019 are presented under ASU 2016-02. Prior period amounts were not adjusted and continue to be reported under previous lease accounting guidance. Under ASU 2016-02, the Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (“ROU”) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable. As the implicit rate in the Company's leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating the Company’s incremental borrowing rates, the Company gives consideration to its credit risk, term of the lease, total lease payments and adjust for the impacts of collateral, as necessary. The lease term used may reflect any option to extend or terminate the lease when it is reasonably certain the Company will exercise such options. Lease expenses for the Company's operating leases are recognized on a straight-line basis over the lease term. ASU 2016-02 provides a number of optional practical expedients in transitioning to ASU 2016-02. The Company has elected the package of practical expedients to avoid reassessing under ASU 2016-02 prior conclusions about lease identification, lease classification and initial direct costs. The Company has also elected the practical expedient allowing the use of hindsight in determining the lease term and assessing impairment of right-of-use ROU assets based on all facts and circumstances through the effective date of the new standard. ASU 2016-02 also provides practical expedients for ongoing lease accounting. The Company has elected the recognition exemption for short-term leases for all leases that qualify. Under this exemption, the Company will not recognize ROU assets or lease liabilities for those leases that qualify as a short-term lease (leases with lease terms of 12 months or less), which includes not recognizing ROU assets or lease liabilities for existing short-term leases in transition. The Company also has elected the practical expedient avoid separating lease and non-lease components for any of its leases within its existing classes of assets. The Company recognized operating lease liabilities of $78.8 and right-of-use assets related to operating leases totaling $74.5 as of the adoption date. These are presented as “Current maturities of operating lease liabilities” for a total of $13.1, “Noncurrent operating lease liabilities” for a total of $65.7, and “Operating lease right-of-use assets” for a total of $74.5 on the Company’s consolidated balance sheet. No adjustments to the beginning retained earnings balance were required. Standards Effective in Future Years and Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326) (“ASU 2016-13”) which introduces new guidance for the accounting for credit losses on certain instruments within its scope. ASU 2016-13 introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. For trade receivables, the Company will be required to use a forward-looking expected loss model rather than the incurred loss model for recognizing credit losses, which reflects losses that are probable. Credit losses relating to available-for-sale debt securities will also be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. ASU 2016-13 is effective for fiscal years beginning after December 31, 2019, including interim periods within those years. Early application of the guidance is permitted for all entities for fiscal years beginning after December 15, 2018, including the interim periods within those fiscal years. Application of the amendments is through a cumulative-effect adjustment to retained earnings as of the effective date. The Company is currently evaluating the impact of ASU 2016-13 on its consolidated financial statements .

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Sep. 30, 2019
Revenue From Contract With Customer [Abstract]
Composition of Total Revenue by Product and U.S versus Rest of World	The following table presents detail regarding the composition of our total revenue by product and U.S versus rest of world, “RoW”: Three months ended September 30, 2019 2018 (In millions) U.S. RoW Total U.S. RoW Total Molecular diagnostic revenues: Hereditary Cancer Testing $ 100.6 $ 3.9 $ 104.5 $ 113.5 $ 2.8 $ 116.3 GeneSight 22.7 — 22.7 29.3 — 29.3 Prenatal 23.5 — 23.5 18.1 — 18.1 VectraDA 11.0 — 11.0 13.0 — 13.0 Prolaris 6.5 — 6.5 6.2 — 6.2 EndoPredict 0.5 1.8 2.3 0.3 2.1 2.4 Other 1.4 0.1 1.5 3.6 0.1 3.7 Total molecular diagnostic revenue 166.2 5.8 172.0 184.0 5.0 189.0 Pharmaceutical and clinical service revenue 8.5 5.9 14.3 7.6 5.7 13.3 Total revenue $ 174.7 $ 11.7 $ 186.3 $ 191.6 $ 10.7 $ 202.3
Reconciliation of Deferred Revenue Balances	A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below: Three months ended September 30, 2019 2018 Deferred revenue - beginning balance $ 2.2 $ 2.6 Revenue recognized (0.4 ) (1.7 ) Prepayments 0.3 1.6 Deferred revenue - Ending Balance $ 2.1 $ 2.5

Acquisitions (Tables)

Acquisitions (Tables)	3 Months Ended
	Sep. 30, 2019
Changes in Carrying Amount of Goodwill	The following summarizes changes to the goodwill balance for the three months ended September 30, 2019 Carrying amount Ending balance June 30 2019 $ 417.2 Acquisitions — Translation adjustments (1.1 ) Ending balance September 30, 2019 $ 416.1
Counsyl Inc [Member]
Allocation of Consideration Transferred	The allocation of the consideration transferred was finalized within the measurement pe riod (which was up to one year from the acquisition date) Estimated Fair Value Current assets $ 42.5 Intangible assets 290.0 Equipment 18.2 Other assets 0.1 Goodwill 99.3 Current liabilities (19.6 ) Long term liabilities (0.1 ) Deferred tax liability (9.2 ) Total fair value purchase price $ 421.2 Less: Cash acquired (15.3 ) Total consideration transferred $ 405.9
Changes in Carrying Amount of Goodwill	Changes in goodwill since the Counsyl acquisition as of September 30, 2019 are shown below: Carrying amount Balance September 30, 2018 $ 94.9 Fair value adjustment to equipment 0.7 Intangible adjustment 2.9 Working capital adjustment (1.1 ) Change in deferred tax liability 1.9 Balance September 30, 2019 $ 99.3
Pro Forma Results of Acquisitions	Accordingly, these unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operation of the combined company would have been if the acquisition had occur red at the beginning of the period presented, nor are they indicative of future results of operations and are not necessarily indicative of results that might have been achieved had the acquisition been consummated as of July 1, 2017. Three months ended September 30, 2019 2018 Revenue $ 186.3 $ 212.5 Income (loss) from operations (20.9 ) 11.5 Net income (loss) (20.6 ) 8.6 Earnings (loss) per share, basic $ (0.28 ) $ 0.11 Earnings (loss) per share, diluted $ (0.28 ) $ 0.11

Marketable Investment Securit_2

Marketable Investment Securities (Tables)	3 Months Ended
	Sep. 30, 2019
Investments Debt And Equity Securities [Abstract]
Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security	The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at September 30, 2019 and June 30, 2019 were as follows: Gross Gross unrealized unrealized Amortized holding holding Estimated cost gains losses fair value At September 30, 2019: Cash and cash equivalents: Cash $ 67.2 $ — $ — $ 67.2 Cash equivalents 22.7 — — $ 22.7 Total cash and cash equivalents 89.9 — — 89.9 Available-for-sale: Corporate bonds and notes 68.7 0.4 69.1 Municipal bonds 15.0 0.1 15.1 Federal agency issues 7.0 — — 7.0 US government securities 12.9 0.1 — 13.0 Total $ 193.5 $ 0.6 $ — $ 194.1 Gross Gross unrealized unrealized Amortized holding holding Estimated cost gains losses fair value At June 30, 2019: Cash and cash equivalents: Cash $ 68.7 $ — $ — $ 68.7 Cash equivalents 24.5 — — 24.5 Total cash and cash equivalents 93.2 — — 93.2 Available-for-sale: Corporate bonds and notes 64.0 0.6 — 64.6 Municipal bonds 15.3 — — 15.3 Federal agency issues 9.0 — — 9.0 US government securities 9.7 — — 9.7 Total $ 191.2 $ 0.6 $ — $ 191.8
Schedule of Maturities of Debt Securities Classified as Cash Equivalents and Available-For-Sale Securities	Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities are as follows at September 30, 2019: Amortized Estimated cost fair value Cash $ 67.2 $ 67.2 Cash equivalents 22.7 22.7 Available-for-sale: Due within one year 54.9 55.0 Due after one year through five years 48.7 49.2 Due after five years — — Total $ 193.5 $ 194.1

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	3 Months Ended
	Sep. 30, 2019
Property Plant And Equipment [Abstract]
Schedule of Property, Plant and Equipment, Net	September 30, June 30, 2019 2019 Land $ 2.2 $ 2.3 Buildings and improvements 18.2 18.8 Leasehold improvements 31.1 31.0 Equipment 115.5 117.1 167.0 169.2 Less accumulated depreciation (112.0 ) (111.9 ) Property, plant and equipment, net $ 55.0 $ 57.3 Three months ended September 30, 2019 2018 Depreciation expense $ 2.9 $ 4.9

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Sep. 30, 2019
Goodwill And Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill	The following summarizes changes to the goodwill balance for the three months ended September 30, 2019 Carrying amount Ending balance June 30 2019 $ 417.2 Acquisitions — Translation adjustments (1.1 ) Ending balance September 30, 2019 $ 416.1
Summarized Amounts Reported as Intangible Assets	The following summarizes the amounts reported as intangible assets Gross Carrying Accumulated Amount Amortization Net At September 30, 2019: Purchased licenses and technologies $ 814.5 $ (171.5 ) $ 643.0 Customer relationships 4.7 (3.9 ) 0.8 Trademarks 3.0 (1.3 ) 1.7 Total amortized intangible assets 822.2 (176.7 ) 645.5 In-process research and development 22.3 — 22.3 Total unamortized intangible assets 22.3 — 22.3 Total intangible assets $ 844.5 $ (176.7 ) $ 667.8 Gross Carrying Accumulated Amount Amortization Net At June 30, 2019: Purchased licenses and technologies $ 815.7 $ (156.6 ) $ 659.1 Customer relationships 4.6 (3.8 ) 0.8 Trademarks 3.0 (1.2 ) 1.8 Total amortized intangible assets 823.3 (161.6 ) 661.7 In-process research and development 23.0 — 23.0 Total unamortized intangible assets 23.0 — 23.0 Total intangible assets $ 846.3 $ (161.6 ) $ 684.7
Amortization for Intangible Assets	The Company recorded amortization expense during the respective periods for these intangible assets as follows: Three months ended September 30, 2019 2018 Amortization of intangible assets $ 15.3 $ 13.4

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Sep. 30, 2019
Payables And Accruals [Abstract]
Summary of Accrued Liabilities	September 30, June 30, 2019 2019 Employee compensation and benefits $ 45.2 $ 48.8 Accrued taxes payable 7.2 3.0 Qui tam settlement 9.1 9.1 Other 11.5 18.0 Total accrued liabilities $ 73.0 $ 78.9

Long-Term Debt (Tables)

Long-Term Debt (Tables)	3 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Schedule of Long-Term Debt	Amounts outstanding under the Amended Facility and Facility were as follows: September 30, June 30, 2019 2019 Long-term debt $ 226.6 $ 235.0 Long-term debt discount (1.6 ) (1.5 ) Net long-term debt $ 225.0 $ 233.5

Other Long Term Liabilities (Ta

Other Long Term Liabilities (Tables)	3 Months Ended
	Sep. 30, 2019
Other Liabilities Disclosure [Abstract]
Summary of Other Long Term Liabilities	September 30, June 30, 2019 2019 Pension obligation 6.8 6.8 Other 0.5 1.0 Total other long term liabilities $ 7.3 $ 7.8

Preferred and Common Stockhol_2

Preferred and Common Stockholder's Equity (Tables)	3 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Summary of Common Shares Issued and Outstanding	Common shares issued and outstanding Three months ended Year ended September 30, June 30, 2019 2019 Beginning common stock issued and outstanding 73.5 70.6 Common stock issued upon exercise of options and employee stock plans 0.9 4.5 Repurchase and retirement of common stock — (1.6 ) Common stock issued and outstanding at end of period 74.4 73.5
Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations	The following is a reconciliation of the denominators of the basic and diluted earnings per share (“EPS”) computations: Three months ended September 30, 2019 2018 Denominator: Weighted-average shares outstanding used to compute basic EPS 73.7 73.0 Effect of dilutive shares — — Weighted-average shares outstanding and dilutive securities used to compute diluted EPS 73.7 73.0
Schedule of Anti-Dilutive Options and Restricted Stock Units Excluded from EPS Computation	These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows: Three months ended September 30, 2019 2018 Anti-dilutive options and RSU's excluded from EPS computation 1.7 4.1
Schedule of Stock Repurchases	The shares retired, aggregate common stock and additional paid-in capital reductions, and related charges to accumulated deficit for the repurchases for three months ended September 30, 2019 and 2018 were as follows: Three months ended September 30, 2019 2018 Shares purchased and retired — — Common stock and additional paid-in-capital reductions $ — $ — Charges to retained earnings $ — $ —

Share-Based Compensation (Table

Share-Based Compensation (Tables)	3 Months Ended
	Sep. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding	A summary of the stock option activity under the Company’s plans for the three months ended September 30, 2019 is as follows: Number of shares Weighted average exercise price Options outstanding at June 30, 2019 5.5 $ 24.45 Options granted — $ — Less: Options exercised (0.4 ) $ 22.87 Options canceled or expired (0.1 ) $ 30.00 Options outstanding at September 30, 2019 5.0 $ 24.39 Options exercisable at September 30, 2019 5.0 $ 24.39
Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding	A summary of the RSU activity under the Company’s plans for the three months ended September 30, 2019 is as follows: Number of shares Weighted average grant date fair value RSUs outstanding at June 30, 2019 2.4 $ 37.70 RSUs granted 1.2 $ 29.89 Less: RSUs vested (0.8 ) $ 36.00 RSUs canceled (0.1 ) $ 46.00 RSUs outstanding at September 30, 2019 2.7 $ 34.71
Schedule of Share-Based Compensation Recognized in Consolidated Statements of Operations	Share-based compensation expense recognized and included in the condensed consolidated statements of income and comprehensive income was allocated as follows: Three months ended September 30, 2019 2018 Cost of molecular diagnostic testing $ 0.2 $ 0.2 Cost of pharmaceutical and clinical services 0.1 0.1 Research and development expense 1.5 1.2 Selling, general, and administrative expense 7.0 6.2 Total share-based compensation expense $ 8.8 $ 7.7

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Financial Assets and Liabilities	The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis: Level 1 Level 2 Level 3 Total September 30, 2019 Money market funds (a) $ 13.3 $ — $ — $ 13.3 Corporate bonds and notes 1.5 69.1 — 70.6 Municipal bonds — 15.1 — 15.1 Federal agency issues — 7.0 — 7.0 US government securities — 13.0 — 13.0 Contingent consideration — — (10.7 ) (10.7 ) Total $ 14.8 $ 104.2 $ (10.7 ) $ 108.3 (a) Money market funds are primarily comprised of exchange traded funds and accrued interest. Level 1 Level 2 Level 3 Total June 30, 2019 Money market funds (a) $ 17.2 $ — $ — $ 17.2 Corporate bonds and notes 2.5 64.4 — 66.9 Municipal bonds — 15.4 — 15.4 Federal agency issues — 9.0 — 9.0 US government securities — 9.8 — 9.8 Contingent consideration — — (13.8 ) (13.8 ) Total $ 19.7 $ 98.6 $ (13.8 ) $ 104.5 (a) Money market funds are primarily comprised of exchange traded funds and accrued interest.
Change in Fair Value of Contingent Consideration	The following table reconciles the change in the fair value of the contingent consideration during the periods presented: Carrying amount Balance June 30, 2019 $ 13.8 Payment of contingent consideration (3.3 ) Change in fair value recognized in the income statement (0.7 ) Translation adjustments recognized in other comprehensive income 0.9 Ending balance September 30, 2019 $ 10.7

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Sep. 30, 2019
Commitments And Contingencies Disclosure [Abstract]
Maturities of Operating Lease Liabilities	As of September 30, 2019, the maturities of the Company’s operating lease liabilities were as follows: Fiscal year ending: 2020 $ 11.9 2021 14.9 2022 13.7 2023 12.6 2024 12.3 Thereafter 19.3 Total lease payments $ 84.7
Future Minimum Lease Payments	The following table summarizes the future minimum lease payments as of June 30, 2019: Fiscal year ending: 2020 $ 15.1 2021 14.1 2022 13.1 2023 12.2 2024 11.9 Thereafter 19.1 Total lease payments $ 85.5

Employee Deferred Savings Plan

Employee Deferred Savings Plan (Tables)	3 Months Ended
	Sep. 30, 2019
Postemployment Benefits [Abstract]
Company Recorded Contributions To Plan	The Company recorded contributions to the plan as follows: Three months ended September 30, 2019 2018 Deferred savings plan contributions $ 2.5 $ 2.0

Segment and Related Informati_2

Segment and Related Information (Tables)	3 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Schedule of Segment Performance Based on Income (Loss) before Interest Income and Other Income and Expense	Segment revenue and operating income (loss) were as follows during the periods presented: Diagnostics Other Total Three months ended September 30, 2019 Revenues $ 170.4 $ 15.9 $ 186.3 Depreciation and amortization 16.9 1.3 18.2 Segment operating income (loss) 17.3 (38.2 ) (20.9 ) Three months ended September 30, 2018 Revenues $ 189.0 $ 13.3 $ 202.3 Depreciation and amortization 17.0 1.3 18.3 Segment operating income 27.6 (26.4 ) 1.2 Three months ended September 30, 2019 2018 Total operating income for reportable segments $ (20.9 ) $ 1.2 Unallocated amounts: Interest income 0.9 0.7 Interest expense (2.9 ) (2.2 ) Other 0.6 1.1 Income (loss) from operations before income taxes (22.3 ) 0.8 Income tax provision (1.7 ) 1.6 Net income (loss) (20.6 ) (0.8 ) Net loss attributable to non-controlling interest — (0.1 ) Net income (loss) attributable to Myriad Genetics, Inc. stockholders $ (20.6 ) $ (0.7 )

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	3 Months Ended
	Sep. 30, 2019
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplemental Cash Flow Information	Three months ended September 30, 2019 2018 Cash paid during the period for income taxes $ 0.2 $ 4.9 Cash paid for interest 2.8 0.9 Establishment of operating lease right-of-use assets and lease liabilities Operating lease right-of-use assets $ 74.5 $ — Operating lease liabilities (78.8 ) — Accrued liabilities and other long-term liabilities 4.3 —

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Detail) $ in Millions	Sep. 30, 2019USD ($)
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Operating lease right-of-use assets	$ 71.3
Operating lease liability current	13
Operating lease liability noncurrent	62.6
ASU 2016-02
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Operating lease liability	78.8
Operating lease right-of-use assets	74.5
Operating lease liability current	13.1
Operating lease liability noncurrent	$ 65.7
Assurex [Member] | Assurex Canada Ltd [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Non controlling interest ownership percentage by parent	85.00%
Centre For Addiction And Mental Health [Member] | Assurex Canada Ltd [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Non controlling interest ownership percentage by noncontrolling owners	15.00%

Revenue - Composition of Total

Revenue - Composition of Total Revenue by Product and U.S versus Rest of World (Detail) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Disaggregation Of Revenue [Line Items]
Total revenue	$ 186.3	$ 202.3
U.S. [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	174.7	191.6
RoW [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	11.7	10.7
Molecular Diagnostic - Hereditary Cancer Testing [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	104.5	116.3
Molecular Diagnostic - Hereditary Cancer Testing [Member] | U.S. [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	100.6	113.5
Molecular Diagnostic - Hereditary Cancer Testing [Member] | RoW [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	3.9	2.8
Molecular Diagnostic - GeneSight [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	22.7	29.3
Molecular Diagnostic - GeneSight [Member] | U.S. [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	22.7	29.3
Molecular Diagnostic - Prenatal [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	23.5	18.1
Molecular Diagnostic - Prenatal [Member] | U.S. [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	23.5	18.1
Molecular Diagnostic- VectraDA [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	11	13
Molecular Diagnostic- VectraDA [Member] | U.S. [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	11	13
Molecular Diagnostic - Prolaris [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	6.5	6.2
Molecular Diagnostic - Prolaris [Member] | U.S. [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	6.5	6.2
Molecular Diagnostic - EndoPredict [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	2.3	2.4
Molecular Diagnostic - EndoPredict [Member] | U.S. [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	0.5	0.3
Molecular Diagnostic - EndoPredict [Member] | RoW [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	1.8	2.1
Molecular Diagnostic - Other [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	1.5	3.7
Molecular Diagnostic - Other [Member] | U.S. [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	1.4	3.6
Molecular Diagnostic - Other [Member] | RoW [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	0.1	0.1
Molecular Diagnostic Testing [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	172	189
Molecular Diagnostic Testing [Member] | U.S. [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	166.2	184
Molecular Diagnostic Testing [Member] | RoW [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	5.8	5
Pharmaceutical and Clinical Services [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	14.3	13.3
Pharmaceutical and Clinical Services [Member] | U.S. [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	8.5	7.6
Pharmaceutical and Clinical Services [Member] | RoW [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	$ 5.9	$ 5.7

Revenue - Reconciliation of Def

Revenue - Reconciliation of Deferred Revenue Balances (Detail) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Revenue From Contract With Customer [Abstract]
Deferred revenue - beginning balance	$ 2.2	$ 2.6
Revenue recognized	(0.4)	(1.7)
Prepayments	0.3	1.6
Deferred revenue - Ending Balance	$ 2.1	$ 2.5

Revenue - Additional Informatio

Revenue - Additional Information (Detail)	3 Months Ended
	Sep. 30, 2019USD ($)$ / shares
Disaggregation Of Revenue [Line Items]
Revenue, practical expedient, remaining performance obligation, description	In accordance with ASU 2014-09, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company’s right to payment is in an amount that directly corresponds with the value of Company’s performance to date. However, periodically the Company enters into arrangements with customers to provide diagnostic testing and/or pharmaceutical and clinical services that may have terms longer than one year and include multiple performance obligations.
Revenue, practical expedient, remaining performance obligation	true
Revenue, practical expedient, initial application and transition, nondisclosure of transaction price allocation to remaining performance obligation	true
Revenue, remaining performance obligation	$ 1,800,000
Capitalized costs incurred to obtain or fulfill contract	$ 0
Revenue practical expedient, incremental cost of obtaining contract	true
Revenue, performance obligation, description of payment terms	This practical expedient has been elected because the Company collects very little cash from customers under payment terms and vast majority of payments terms have a payback period of less than one year.
Revenue increase (decrease) performance obligation	$ (10,900,000)
Earnings per share increase (decrease) performance obligation | $ / shares	$ (0.11)

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail) - Counsyl Inc [Member] $ / shares in Units, $ in Millions	Jul. 31, 2018USD ($)$ / sharesshares
Business Acquisition [Line Items]
Business acquisition consideration	$ 405.9
Acquisition costs	6.8
Acquired intangible assets	290
Developed Screening Processes [Member]
Business Acquisition [Line Items]
Acquired intangible assets	$ 290
Intangible assets estimated useful lives	12 years
Developed Screening Processes [Member] | Measurement Input, Discount Rate [Member]
Business Acquisition [Line Items]
Estimated net cash flows, discount rate	12.5
Agreement and Plan of Merger [Member]
Business Acquisition [Line Items]
Effective date of business acquisition	Jul. 31, 2018
Business acquisition consideration	$ 405.9
Cash payment on business acquisition	278.5
Amount of cash consideration deposited in escrow account	$ 5
Agreement and Plan of Merger [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Business acquisition, shares issued | shares	2,994,251
Business acquisition, shares issued, value	$ 127.4
Business acquisition, per share market closing price | $ / shares	$ 42.53

Acquisitions - Allocation of Co

Acquisitions - Allocation of Consideration Transferred (Detail) - USD ($) $ in Millions	Jul. 31, 2018	Sep. 30, 2019	Jun. 30, 2019	Sep. 30, 2018
Business Acquisition [Line Items]
Goodwill		$ 416.1	$ 417.2
Counsyl Inc [Member]
Business Acquisition [Line Items]
Current assets	$ 42.5
Intangible assets	290
Equipment	18.2
Other assets	0.1
Goodwill	99.3	$ 99.3		$ 94.9
Current liabilities	(19.6)
Long term liabilities	(0.1)
Deferred tax liability	(9.2)
Total fair value purchase price	421.2
Less: Cash acquired	(15.3)
Total consideration transferred	$ 405.9

Acquisitions - Summary of Chang

Acquisitions - Summary of Changes to Goodwill Balance (Detail) $ in Millions	12 Months Ended
	Sep. 30, 2019USD ($)
Goodwill [Line Items]
Ending balance	$ 416.1
Counsyl Inc [Member]
Goodwill [Line Items]
Beginning balance	94.9
Fair value adjustment to equipment	0.7
Intangible adjustment	2.9
Working capital adjustment	(1.1)
Change in deferred tax liability	1.9
Ending balance	$ 99.3

Acquisitions - Pro Forma Result

Acquisitions - Pro Forma Results of Acquisitions (Detail) - Counsyl Inc [Member] - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Business Acquisition [Line Items]
Revenue	$ 186.3	$ 212.5
Income (loss) from operations	(20.9)	11.5
Net income (loss)	$ (20.6)	$ 8.6
Earnings (loss) per share, basic	$ (0.28)	$ 0.11
Earnings (loss) per share, diluted	$ (0.28)	$ 0.11

Marketable Investment Securit_3

Marketable Investment Securities - Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Detail) - USD ($) $ in Millions	Sep. 30, 2019	Jun. 30, 2019
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Amortized cost	$ 89.9	$ 93.2
Available-for-sale, Amortized cost	193.5	191.2
Gross unrealized holding gains	0.6	0.6
Available-for-sale, Estimated fair value	194.1	191.8
Amortized cost	193.5	191.2
Estimated fair value	194.1	191.8
Cash [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Amortized cost	67.2	68.7
Cash and cash equivalents, Estimated fair value	67.2	68.7
Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Amortized cost	22.7	24.5
Cash and cash equivalents, Estimated fair value	22.7	24.5
Total Cash and Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Amortized cost	89.9	93.2
Cash and cash equivalents, Estimated fair value	89.9	93.2
Corporate Bonds and Notes [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale, Amortized cost	68.7	64
Gross unrealized holding gains	0.4	0.6
Available-for-sale, Estimated fair value	69.1	64.6
Municipal Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale, Amortized cost	15	15.3
Gross unrealized holding gains	0.1
Available-for-sale, Estimated fair value	15.1	15.3
Federal Agency Issues [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale, Amortized cost	7	9
Available-for-sale, Estimated fair value	7	9
US Government Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale, Amortized cost	12.9	9.7
Gross unrealized holding gains	0.1
Available-for-sale, Estimated fair value	$ 13	$ 9.7

Marketable Investment Securit_4

Marketable Investment Securities - Schedule of Maturities of Debt Securities Classified as Cash Equivalents and Available-For-Sale Securities (Detail) - USD ($) $ in Millions	Sep. 30, 2019	Jun. 30, 2019
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Amortized cost	$ 89.9	$ 93.2
Due within one year, Amortized cost	54.9
Due after one year through five years, Amortized cost	48.7
Due after five years, Amortized cost	0
Total, Amortized cost	193.5	191.2
Due within one year, Estimated fair value	55
Due after one year through five years, Estimated fair value	49.2
Due after five years, Estimated fair value	0
Total, Estimated fair value	194.1	191.8
Cash [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Amortized cost	67.2	68.7
Cash equivalents, Estimated fair value	67.2	68.7
Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Amortized cost	22.7	24.5
Cash equivalents, Estimated fair value	$ 22.7	$ 24.5

Property, Plant and Equipment_3

Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, Net (Detail) - USD ($) $ in Millions	Sep. 30, 2019	Jun. 30, 2019
Property Plant And Equipment [Abstract]
Land	$ 2.2	$ 2.3
Buildings and improvements	18.2	18.8
Leasehold improvements	31.1	31
Equipment	115.5	117.1
Gross property, plant and equipment	167	169.2
Less accumulated depreciation	(112)	(111.9)
Property, plant and equipment, net	$ 55	$ 57.3

Property, Plant and Equipment_4

Property, Plant and Equipment, Net - Schedule of Depreciation Expense (Detail) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Property Plant And Equipment [Abstract]
Depreciation expense	$ 2.9	$ 4.9

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	Sep. 30, 2019	Jun. 30, 2019
Goodwill And Intangible Assets [Line Items]
Goodwill	$ 416.1	$ 417.2
Diagnostics [Member]
Goodwill And Intangible Assets [Line Items]
Goodwill	350.8
Other [Member]
Goodwill And Intangible Assets [Line Items]
Goodwill	$ 65.3

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Summary of Changes to Goodwill Balance (Detail) $ in Millions	3 Months Ended
	Sep. 30, 2019USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Beginning balance	$ 417.2
Translation adjustments	(1.1)
Ending balance	$ 416.1

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Summarized Amounts Reported as Intangible Assets (Detail) - USD ($) $ in Millions	Sep. 30, 2019	Jun. 30, 2019
Intangible Assets [Line Items]
Gross Carrying Amount, amortized intangible assets	$ 822.2	$ 823.3
Gross Carrying Amount, total intangible assets	844.5	846.3
Accumulated Amortization	(176.7)	(161.6)
Net, amortized intangible assets	645.5	661.7
Net, total intangible assets	667.8	684.7
Net, non-amortizable intangible assets	22.3	23
In-Process Research and Development [Member]
Intangible Assets [Line Items]
Net, non-amortizable intangible assets	22.3	23
Purchased Licenses and Technologies [Member]
Intangible Assets [Line Items]
Gross Carrying Amount, amortized intangible assets	814.5	815.7
Accumulated Amortization	(171.5)	(156.6)
Net, amortized intangible assets	643	659.1
Customer Relationships [Member]
Intangible Assets [Line Items]
Gross Carrying Amount, amortized intangible assets	4.7	4.6
Accumulated Amortization	(3.9)	(3.8)
Net, amortized intangible assets	0.8	0.8
Trademarks [Member]
Intangible Assets [Line Items]
Gross Carrying Amount, amortized intangible assets	3	3
Accumulated Amortization	(1.3)	(1.2)
Net, amortized intangible assets	$ 1.7	$ 1.8

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Amortization on Intangible Assets (Detail) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Goodwill And Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 15.3	$ 13.4

Accrued Liabilities - Summary o

Accrued Liabilities - Summary of Accrued Liabilities (Detail) - USD ($) $ in Millions	Sep. 30, 2019	Jun. 30, 2019
Payables And Accruals [Abstract]
Employee compensation and benefits	$ 45.2	$ 48.8
Accrued taxes payable	7.2	3
Qui tam settlement	9.1	9.1
Other	11.5	18
Total accrued liabilities	$ 73	$ 78.9

Long Term Debt - Additional Inf

Long Term Debt - Additional Information (Detail) - USD ($)	Jul. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Jun. 30, 2019	Dec. 23, 2016
Debt Instrument [Line Items]
Aggregate principal amount of loan		$ 226,600,000		$ 235,000,000
Long term debt, net		225,000,000		$ 233,500,000
Principal repayment		8,600,000	$ 40,000,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Principal repayment		$ 8,600,000
Revolving Credit Facility [Member] | Amendment to Credit Agreement [Member]
Debt Instrument [Line Items]
Aggregate principal amount of loan	$ 300,000,000
Upfront fees	1,800,000
Debt issuance costs	300,000
Long term debt, net	225,000,000
Scheduled principal payments prior to maturity date	$ 0
Revolving Credit Facility [Member] | Counsyl Inc [Member] | Amendment to Credit Agreement [Member]
Debt Instrument [Line Items]
Loan agreement, maturity date	Jul. 31, 2023
Loans maximum borrowing capacity	$ 350,000,000				$ 300,000,000

Long-Term Debt - Schedule of Lo

Long-Term Debt - Schedule of Long-Term Debt (Detail) - USD ($) $ in Millions	Sep. 30, 2019	Jun. 30, 2019
Long-term Debt, Unclassified [Abstract]
Long-term debt	$ 226.6	$ 235
Long-term debt discount	(1.6)	(1.5)
Net long-term debt	$ 225	$ 233.5

Other Long Term Liabilities - S

Other Long Term Liabilities - Summary of Other Long Term Liabilities (Detail) - USD ($) $ in Millions	Sep. 30, 2019	Jun. 30, 2019
Other Liabilities Disclosure [Abstract]
Pension obligation	$ 6.8	$ 6.8
Other	0.5	1
Total other long term liabilities	$ 7.3	$ 7.8

Other Long Term Liabilities - A

Other Long Term Liabilities - Additional Information (Detail) $ in Millions	Sep. 30, 2019USD ($)plan	Jun. 30, 2019USD ($)
Other Liabilities Disclosure [Abstract]
Number of defined benefit pension plans | plan	2
Fair value of plan assets	$ 0.1
Net pension liability	$ 6.8	$ 6.8

Preferred and Common Stockhol_3

Preferred and Common Stockholder's Equity - Additional Information (Detail) - USD ($)	Sep. 30, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2016
Class of Stock [Line Items]
Preferred stock, shares authorized	5,000,000
Preferred stock, par value	$ 0.01
Preferred stock, shares outstanding	0
Common stock, shares authorized	150,000,000
Common stock, par value	$ 0.01
Common stock, shares issued	74,400,000	73,500,000	70,600,000
Common stock, shares outstanding	74,400,000	73,500,000	70,600,000
Share repurchase program, remaining authorized repurchase amount	$ 110,700,000
Eighth Share Repurchase Program [Member]
Class of Stock [Line Items]
Share repurchase program, authorized amount				$ 200,000,000

Preferred and Common Stockhol_4

Preferred and Common Stockholder's Equity - Summary of Common Shares Issued and Outstanding (Detail) - shares shares in Millions	3 Months Ended	12 Months Ended
	Sep. 30, 2019	Jun. 30, 2019
Equity [Abstract]
Beginning common stock issued, Beginning balance	73.5	70.6
Beginning common stock outstanding, Beginning balance	73.5	70.6
Common stock issued upon exercise of options and employee stock plans	0.9	4.5
Repurchase and retirement of common stock		(1.6)
Common stock issued, Ending balance	74.4	73.5
Common stock outstanding, Ending balance	74.4	73.5

Preferred and Common Stockhol_5

Preferred and Common Stockholder's Equity - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Detail) - shares shares in Millions	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Equity [Abstract]
Weighted-average shares outstanding used to compute basic EPS	73.7	73
Weighted-average shares outstanding and dilutive securities used to compute diluted EPS	73.7	73

Preferred and Common Stockhol_6

Preferred and Common Stockholder's Equity - Schedule of Anti-Dilutive Options and Restricted Stock Units Excluded from EPS Computation (Detail) - shares shares in Millions	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Equity [Abstract]
Anti-dilutive options and RSU's excluded from EPS computation	1.7	4.1

Preferred and Common Stockhol_7

Preferred and Common Stockholder's Equity - Schedule of Stock Repurchases (Detail) shares in Millions	12 Months Ended
	Jun. 30, 2019shares
Stockholders Equity [Line Items]
Shares purchased and retired	1.6

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Jun. 30, 2020
Income Tax Contingency [Line Items]
Income tax expense (benefit)	$ (1.7)	$ 1.6
Approximate rate on pre-tax income	7.60%	200.00%
State Tax Authority [Member] | Earliest Tax Year [Member] | State of New Jersey [Member]
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination	2013
State Tax Authority [Member] | Earliest Tax Year [Member] | State of New York [Member]
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination	2014
State Tax Authority [Member] | Earliest Tax Year [Member] | State of Massachusetts [Member]
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination	2014
State Tax Authority [Member] | Latest Tax Year [Member] | State of New Jersey [Member]
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination	2017
State Tax Authority [Member] | Latest Tax Year [Member] | State of New York [Member]
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination	2016
State Tax Authority [Member] | Latest Tax Year [Member] | State of Massachusetts [Member]
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination	2016
Foreign Tax Authority [Member] | Earliest Tax Year [Member] | Federal Ministry of Finance, Germany [Member]
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination	2013
Foreign Tax Authority [Member] | Earliest Tax Year [Member] | Switzerland Federal Tax Administration [Member]
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination	2015
Foreign Tax Authority [Member] | Latest Tax Year [Member] | Federal Ministry of Finance, Germany [Member]
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination	2015
Foreign Tax Authority [Member] | Latest Tax Year [Member] | Switzerland Federal Tax Administration [Member]
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination	2016
Scenario Forecast [Member]
Income Tax Contingency [Line Items]
U.S. federal statutory rate			21.00%

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2019	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, description		Options and restricted stock units granted to our non-employee directors vest in full upon completion of one year of service on the Board following the date of the grant.
Total unrecognized share-based compensation cost related to stock options		$ 0
Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Service period of share-based compensation vested, years		4 years
Stock options [Member] | Share-based compensation granted after December 5, 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expire from date of grant, years		8 years
Stock options [Member] | Share-based compensation granted prior to December 5, 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expire from date of grant, years		10 years
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Service period of share-based compensation vested, years	4 years
Total unrecognized share-based compensation cost related to RSUs		$ 39.2
Total unrecognized share-based compensation cost, weighted-average period, years		2 years 8 months 12 days
Restricted Stock Units (RSUs) [Member] | Non Employee Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Service period of share-based compensation vested, years		1 year
The 2017 Plan [Member] | Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grant		400,000
The 2010 Plan [Member] | Options and Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grant		5,300,000
2012 Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares approved			2,000,000
Shares issued under the Plan		600,000

Share-Based Compensation - Sche

Share-Based Compensation - Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding (Detail) shares in Millions	3 Months Ended
	Sep. 30, 2019$ / sharesshares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options outstanding at beginning of period, Number of shares | shares	5.5
Options granted, Number of shares | shares	0
Options exercised, Number of shares | shares	(0.4)
Options canceled or expired, Number of shares | shares	(0.1)
Options outstanding at end of year, Number of shares | shares	5
Options exercisable at end of period, Number of shares | shares	5
Options outstanding at beginning of period, Weighted average exercise price | $ / shares	$ 24.45
Options granted, Weighted average exercise price | $ / shares	0
Options exercised, Weighted average exercise price | $ / shares	22.87
Options canceled or expired, Weighted average exercise price | $ / shares	30
Options outstanding at end of year, Weighted average exercise price | $ / shares	24.39
Options exercisable at end of period, Weighted average exercise price | $ / shares	$ 24.39

Share-Based Compensation - Sc_2

Share-Based Compensation - Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding (Detail) - Restricted Stock Units (RSUs) [Member] shares in Millions	3 Months Ended
	Sep. 30, 2019$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSUs outstanding at beginning of period, Number of shares | shares	2.4
RSUs granted, Number of shares | shares	1.2
RSUs vested, Number of shares | shares	(0.8)
RSUs canceled, Number of shares | shares	(0.1)
RSUs outstanding at end of period, Number of shares | shares	2.7
RSUs outstanding at beginning of period, Weighted average grant date fair value | $ / shares	$ 37.70
RSUs granted, Weighted average grant date fair value | $ / shares	29.89
RSUs vested, Weighted average grant date fair value | $ / shares	36
RSUs canceled, Weighted average grant date fair value | $ / shares	46
RSUs outstanding at end of period, Weighted average grant date fair value | $ / shares	$ 34.71

Share-Based Compensation - Sc_3

Share-Based Compensation - Schedule of Share-Based Compensation Recognized in Consolidated Statements of Operations (Detail) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	$ 8.8	$ 7.7
Molecular Diagnostic Testing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	0.2	0.2
Pharmaceutical and Clinical Services Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	0.1	0.1
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	1.5	1.2
Selling, General, and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	$ 7	$ 6.2

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) $ in Millions	Sep. 30, 2019USD ($)
Level 3 [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Estimated fair value of long-term debt	$ 224.7

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value of Financial Assets and Liabilities (Detail) - USD ($) $ in Millions		Sep. 30, 2019	Jun. 30, 2019
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets and liability		$ 108.3	$ 104.5
Money Market Funds [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets	[1]	13.3	17.2
Corporate Bonds and Notes [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		70.6	66.9
Municipal Bonds [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		15.1	15.4
Federal Agency Issues [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		7	9
US Government Securities [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		13	9.8
Contingent Consideration [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial liability		(10.7)	(13.8)
Level 1 [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets and liability		14.8	19.7
Level 1 [Member] | Money Market Funds [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets	[1]	13.3	17.2
Level 1 [Member] | Corporate Bonds and Notes [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		1.5	2.5
Level 2 [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets and liability		104.2	98.6
Level 2 [Member] | Corporate Bonds and Notes [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		69.1	64.4
Level 2 [Member] | Municipal Bonds [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		15.1	15.4
Level 2 [Member] | Federal Agency Issues [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		7	9
Level 2 [Member] | US Government Securities [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		13	9.8
Level 3 [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets and liability		(10.7)	(13.8)
Level 3 [Member] | Contingent Consideration [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial liability		$ (10.7)	$ (13.8)
[1]	Money market funds are primarily comprised of exchange traded funds and accrued interest.

Fair Value Measurements - Chang

Fair Value Measurements - Change in Fair Value of Contingent Consideration (Detail) $ in Millions	3 Months Ended
	Sep. 30, 2019USD ($)
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]
Balance June 30, 2019	$ 13.8
Payment of contingent consideration	(3.3)
Change in fair value recognized in the income statement	(0.7)
Translation adjustments recognized in other comprehensive income	0.9
Ending balance September 30, 2019	$ 10.7

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Millions	Jul. 18, 2019	Oct. 31, 2019	Sep. 30, 2019
Commitments and Contingencies [Line Items]
Settlement agreement date	July 18, 2019
Settlement amount	$ 9.1
Operating lease weighted average remaining lease term			6 years
Operating lease weighted average discount rate percent			3.87%
Operating Expense [Member]
Commitments and Contingencies [Line Items]
Lease cost			$ 4.6
Variable lease expense			0.6
Short-term lease expense			$ 0.1
Minimum [Member] | Office Spaces, Research and Development Laboratory Facilities, Vehicles and Office Equipment [Member]
Commitments and Contingencies [Line Items]
Remaining lease term period			1 year
Maximum [Member] | Office Spaces, Research and Development Laboratory Facilities, Vehicles and Office Equipment [Member]
Commitments and Contingencies [Line Items]
Remaining lease term period			6 years
Subsequent Event [Member]
Commitments and Contingencies [Line Items]
Settlement amount paid		$ 9.1

Commitments and Contingencies_2

Commitments and Contingencies - Maturities of Operating Lease Liabilities (Detail) $ in Millions	Sep. 30, 2019USD ($)
Commitments And Contingencies Disclosure [Abstract]
2020	$ 11.9
2021	14.9
2022	13.7
2023	12.6
2024	12.3
Thereafter	19.3
Total lease payments	$ 84.7

Commitments and Contingencies_3

Commitments and Contingencies - Future Minimum Lease Payments (Detail) $ in Millions	Jun. 30, 2019USD ($)
Commitments And Contingencies Disclosure [Abstract]
2020	$ 15.1
2021	14.1
2022	13.1
2023	12.2
2024	11.9
Thereafter	19.1
Total lease payments	$ 85.5

Employee Deferred Savings Pla_2

Employee Deferred Savings Plan - Additional Information (Detail)	3 Months Ended
	Sep. 30, 2019
Compensation And Retirement Disclosure [Abstract]
Percent of employee contribution to deferred savings plan	50.00%
Employer's contribution not to exceed percentage of the employees compensation	4.00%

Employee Deferred Savings Pla_3

Employee Deferred Savings Plan - Company Recorded Contributions To Plan (Detail) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Compensation And Retirement Disclosure [Abstract]
Deferred savings plan contributions	$ 2.5	$ 2

Segment and Related Informati_3

Segment and Related Information - Additional Information (Detail)	3 Months Ended
	Sep. 30, 2019Segment
Segment Reporting [Abstract]
Number of reportable segment	2

Segment and Related Informati_4

Segment and Related Information - Schedule of Segment Performance Based on Income (Loss) before Interest Income and Other Income and Expense (Detail) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Segment Reporting Information [Line Items]
Revenues	$ 186.3	$ 202.3
Depreciation and amortization	18.2	18.3
Segment operating income (loss)	(20.9)	1.2
Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenues	170.4	189
Depreciation and amortization	16.9	17
Segment operating income (loss)	17.3	27.6
Other [Member]
Segment Reporting Information [Line Items]
Revenues	15.9	13.3
Depreciation and amortization	1.3	1.3
Segment operating income (loss)	$ (38.2)	$ (26.4)

Segment and Related Informati_5

Segment and Related Information - Schedule of Total Operating Income for Reportable Segments (Detail) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Segment Reporting [Abstract]
Total operating income for reportable segments	$ (20.9)	$ 1.2
Interest income	0.9	0.7
Interest expense	(2.9)	(2.2)
Other	0.6	1.1
Income (loss) before income tax	(22.3)	0.8
Income tax provision (benefit)	(1.7)	1.6
Net income (loss)	(20.6)	(0.8)
Net loss attributable to non-controlling interest		(0.1)
Net income (loss) attributable to Myriad Genetics, Inc. stockholders	$ (20.6)	$ (0.7)

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash paid during the period for income taxes	$ 0.2	$ 4.9
Cash paid for interest	2.8	$ 0.9
Establishment of operating lease right-of-use assets and lease liabilities
Operating lease right-of-use assets	71.3
Accrued liabilities and other long-term liabilities	4.3
ASU 2016-02
Establishment of operating lease right-of-use assets and lease liabilities
Operating lease right-of-use assets	74.5
Operating lease liabilities	$ (78.8)